ZYVERSA THERAPEUTICS INC (ZVSA) Stock Price, Quote, News and Overview
NASDAQ:ZVSA - Nasdaq - US98987D3008 - Common Stock - Currency: USD
ZVSA Quote, Performance and Key Statistics
1.22
0 (0%)
The current stock price of ZVSA is 1.22 USD. In the past month the price decreased by -12.86%. In the past year, price decreased by -84.77%.
ZVSA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.85 | 354.98B | ||
| AMGN | AMGEN INC | 15.03 | 159.99B | ||
| GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
| NTRA | NATERA INC | N/A | 22.20B | ||
| BIIB | BIOGEN INC | 8.32 | 19.98B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
Related stock screener links
About ZVSA
Company Profile
Zyversa Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Weston, Florida and currently employs 7 full-time employees. The company went IPO on 2021-12-21. ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The firm is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). VAR 200’s active ingredient, 2HBCD, is comprised of seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Company Info
ZYVERSA THERAPEUTICS INC
2200 N. Commerce Parkway, Suite 208
Weston FLORIDA US
Employees: 7
Company Website: https://www.zyversa.com/
Investor Relations: https://investors.zyversa.com/
Phone: 17542311688
ZYVERSA THERAPEUTICS INC / ZVSA FAQ
What is the stock price of ZYVERSA THERAPEUTICS INC today?
The current stock price of ZVSA is 1.22 USD.
What is the ticker symbol for ZYVERSA THERAPEUTICS INC stock?
The exchange symbol of ZYVERSA THERAPEUTICS INC is ZVSA and it is listed on the Nasdaq exchange.
On which exchange is ZVSA stock listed?
ZVSA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZYVERSA THERAPEUTICS INC stock?
8 analysts have analysed ZVSA and the average price target is 122.4 USD. This implies a price increase of 9932.79% is expected in the next year compared to the current price of 1.22. Check the ZYVERSA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZYVERSA THERAPEUTICS INC worth?
ZYVERSA THERAPEUTICS INC (ZVSA) has a market capitalization of 3.06M USD. This makes ZVSA a Nano Cap stock.
How many employees does ZYVERSA THERAPEUTICS INC have?
ZYVERSA THERAPEUTICS INC (ZVSA) currently has 7 employees.
What are the support and resistance levels for ZYVERSA THERAPEUTICS INC (ZVSA) stock?
ZYVERSA THERAPEUTICS INC (ZVSA) has a support level at 1.22 and a resistance level at 1.24. Check the full technical report for a detailed analysis of ZVSA support and resistance levels.
Should I buy ZYVERSA THERAPEUTICS INC (ZVSA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZVSA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZVSA, evaluating the profitability, health, valuation and growth aspects
- ZYVERSA THERAPEUTICS INC (ZVSA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZYVERSA THERAPEUTICS INC (ZVSA) Sales and EPS estimates to see what analysts future expectations are.
- ZYVERSA THERAPEUTICS INC (ZVSA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZYVERSA THERAPEUTICS INC (ZVSA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZYVERSA THERAPEUTICS INC (ZVSA) Stock Chart to make your own analysis
- ZYVERSA THERAPEUTICS INC (ZVSA) Latest news and press-releases to stay up to date.
Does ZYVERSA THERAPEUTICS INC (ZVSA) stock pay dividends?
ZVSA does not pay a dividend.
When does ZYVERSA THERAPEUTICS INC (ZVSA) report earnings?
ZYVERSA THERAPEUTICS INC (ZVSA) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of ZYVERSA THERAPEUTICS INC (ZVSA)?
ZYVERSA THERAPEUTICS INC (ZVSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-147.07).
What is the Short Interest ratio of ZYVERSA THERAPEUTICS INC (ZVSA) stock?
The outstanding short interest for ZYVERSA THERAPEUTICS INC (ZVSA) is 5.18% of its float. Check the ownership tab for more information on the ZVSA short interest.
ZVSA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ZVSA. When comparing the yearly performance of all stocks, ZVSA is a bad performer in the overall market: 93.52% of all stocks are doing better.
ZVSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZVSA. ZVSA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ZVSA Financial Highlights
Over the last trailing twelve months ZVSA reported a non-GAAP Earnings per Share(EPS) of -147.07. The EPS increased by 96.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.81% | ||
| ROE | -303.53% | ||
| Debt/Equity | 0 |
ZVSA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ZVSA. The Buy consensus is the average rating of analysts ratings from 8 analysts.